D-Chiro-inositol in PCOS: the myths and what we know about the reality

References

• Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. 2016. A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016:3204083.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Dragotto J, Giuliani A, Bizzarri M. 2019. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. J Cell Physiol. 234(6):9387–9398.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Dragotto J, Lucarelli M, Di Emidio G, Monastra G, Tatone C. 2021. High doses of D-chiro-inositol alone induce a PCO-like syndrome and other alterations in mouse ovaries. Int J Mol Sci. 22(11):5691.
   PubMed Web of Science ®Google Scholar
• Cianci A, Vitale SG. 2022. D-Chiro-inositol and PCOS: between myth and reality. The never-ending story. Int J Food Sci Nutr. 73:1–6.
   PubMed Web of Science ®Google Scholar
• Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, Laganà AS, Chan S-Y, Bevilacqua A, Pkhaladze L, et al. 2021. Inositols: From Established Knowledge to Novel Approaches. IJMS. 22(19):10575.
   Google Scholar
• Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. 2021. The use of D-chiro-Inositol in clinical practice. Eur Rev Med Pharmacol Sci. 25(1):438–446.
   PubMed Web of Science ®Google Scholar
• Gambioli R, Montanino Oliva M, Nordio M, Chiefari A, Puliani G, Unfer V. 2021. New Insights into the Activities of D-Chiro-Inositol: A Narrative Review. Biomedicines. 9(10):1378. eng.
   PubMed Web of Science ®Google Scholar
• Heimark D, McAllister J, Larner J. 2014. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 61(2):111–117.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Unfer V. 2019. D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets. Eur Rev Med Pharmacol Sci. 23(24):10575–10576.
   PubMed Web of Science ®Google Scholar
• Le Donne M, Metro D, Alibrandi A, Papa M, Benvenga S. 2019. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 23(5):2293–2301.
   PubMed Web of Science ®Google Scholar
• Minozzi M, Nordio M, Pajalich R. 2013. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 17(4):537–540.
   PubMed Web of Science ®Google Scholar
• Monastra G, Vazquez-Levin M, Bezerra Espinola MS, Bilotta G, Laganà AS, Unfer V. 2021. D-chiro-inositol, an aromatase down-modulator, increases androgens and reduces estrogens in male volunteers: a pilot study. Basic Clin Androl. 31(1):13.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. 1998. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 83(6):2001–2005.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. 1999. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 340(17):1314–1320.
   PubMed Web of Science ®Google Scholar
• Nordio M, Basciani S, Camajani E. 2019. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 23(12):5512–5521.
   PubMed Web of Science ®Google Scholar
• Nordio M, Kumanov P, Chiefari A, Puliani G. 2021. D-Chiro-Inositol improves testosterone levels in older hypogonadal men with low-normal testosterone: a pilot study. Basic Clin Androl. 31(1):28. eng.
   PubMed Web of Science ®Google Scholar
• Ravanos K, Monastra G, Pavlidou T, Goudakou M, Prapas N. 2017. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 21(23):5491–5498.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marinaro F, Tondelli D, Lui J, Xella S, Marsella T, Tagliasacchi D, Argento C, Tirelli A, Giulini S, et al. 2016. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod Biol Endocrinol. 14(1):52. eng.
   PubMedGoogle Scholar
• Schneider S. 2015. Inositol transport proteins. FEBS Lett. 589(10):1049–1058.
   PubMed Web of Science ®Google Scholar
• Unfer V, Porcaro G. 2014. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 7(5):623–631.
   PubMed Web of Science ®Google Scholar